

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

VILEN et al.

Serial No.: 09/513,024

Filed: February 25, 2000

Atty. File No.: 2879-64

For: "PRODUCT AND METHOD FOR
TREATMENT OF CONDITIONS
ASSOCIATED WITH RECEPTOR-
DESENSITIZATION"

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the Examiner's review of the above-identified patent application on the merits, please amend the above-identified patent application as follows.

IN THE SPECIFICATION:

On page 37, line 11, after "CAHDWRSGFGGFQHLCCGAAGA", please insert -(SEQ ID NO:1)-.

REMARKS

This Response is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 24, 2000. A copy of the Notice is attached hereto. Pursuant to 37 CFR § 1.825(a) and (b) and § 1.821(f), Applicants' agent hereby asserts that the content of the paper and computer readable copies of SEQ ID NO:1 submitted herewith are identical and include no new matter.


The amendment to the specification inserts the sequence identifier from the added Sequence Listing into the specification as required by 37 CFR 1.821(d). Applicants submit that this amendment is formal in nature and does not add any new matter.



Group Art Unit: 1644

Examiner: J. Roark

AMENDMENT AND RESPONSE



RECEIVED
NOV 20 2003

TECH CENTER 1600/2900

RECEIVED
NOV 21 2000

TECH CENTER 1600/2900

#10a 11/25/00
Box 56 ND \$